Mycenax Biotech Cash Flow Reinvestment Rate

Latest as of March 2025: 7.62x

Mycenax Biotech cash flow reinvestment rate. Mycenax Biotech (4726) has a Cash Flow Reinvestment Rate of 7.62x as of March 2025, reinvesting NT$108.92 Million (capex NT$84.30 Million plus investments NT$-24.62 Million) from operating cash flow of NT$14.29 Million. Explore 4726 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

7.62x

(Capex + Investments) / Operating CF

Total Reinvested

NT$108.92 Million

Capex + Investments

Operating Cash Flow

NT$14.29 Million

TWD

Capital Expenditures

NT$84.30 Million

TWD

Cash Flow Reinvestment Rate of Mycenax Biotech (2020–2020)

Cash flow reinvestment rate of Mycenax Biotech from 2020 to 2020. Historical reinvestment intensity for Mycenax Biotech across 1 annual periods. Explore Mycenax Biotech (4726) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.

Mycenax Biotech Cash Flow Reinvestment Rate by Year (2020–2020)

Mycenax Biotech cash flow reinvestment rate by year from 2020 to 2020. Year-by-year capital reinvestment analysis for Mycenax Biotech. For the full cash flow conversion analysis, see Mycenax Biotech cash flow conversion.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2020	1.62x	NT$282.34 Million	NT$174.17 Million	NT$260.22 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow